Abstract:Clinical and Translational MedicineVolume 10, Issue 4 e157 LETTER TO EDITOROpen Access An optimized integrin α6-targeted peptide for positron emission tomography/magnetic resonance imaging of pancreatic cancer and its precancerous lesion Yan Mei, Yan Mei State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorYing-He Li, Ying-He Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorXiao-Chun Yang, Xiao-Chun Yang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorChao Zhou, Chao Zhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorZhi-Jian Li, Zhi-Jian Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorXiao-Bin Zheng, Xiao-Bin Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorJia-Cong Ye, Jia-Cong Ye State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorCheng Li, Cheng Li School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, ChinaSearch for more papers by this authorXuan-Hong Zhang, Xuan-Hong Zhang Experimental Equipment Management Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, ChinaSearch for more papers by this authorJian-Min Yuan, Jian-Min Yuan Central Research Institute UIH Group, Shanghai, ChinaSearch for more papers by this authorHui-Qiang Huang, Hui-Qiang Huang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei Fan, Wei Fan State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei-Guang Zhang, Corresponding Author Wei-Guang Zhang zhangwg@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorMu-Sheng Zeng, Corresponding Author Mu-Sheng Zeng zengmsh@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorGuo-Kai Feng, Corresponding Author Guo-Kai Feng fengguok@sysucc.org.cn orcid.org/0000-0002-8251-291X State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this author Yan Mei, Yan Mei State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorYing-He Li, Ying-He Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorXiao-Chun Yang, Xiao-Chun Yang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China These authors contributed equally to this study.Search for more papers by this authorChao Zhou, Chao Zhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorZhi-Jian Li, Zhi-Jian Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorXiao-Bin Zheng, Xiao-Bin Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorJia-Cong Ye, Jia-Cong Ye State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorCheng Li, Cheng Li School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, ChinaSearch for more papers by this authorXuan-Hong Zhang, Xuan-Hong Zhang Experimental Equipment Management Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, ChinaSearch for more papers by this authorJian-Min Yuan, Jian-Min Yuan Central Research Institute UIH Group, Shanghai, ChinaSearch for more papers by this authorHui-Qiang Huang, Hui-Qiang Huang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei Fan, Wei Fan State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaSearch for more papers by this authorWei-Guang Zhang, Corresponding Author Wei-Guang Zhang zhangwg@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorMu-Sheng Zeng, Corresponding Author Mu-Sheng Zeng zengmsh@sysucc.org.cn State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this authorGuo-Kai Feng, Corresponding Author Guo-Kai Feng fengguok@sysucc.org.cn orcid.org/0000-0002-8251-291X State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China Correspondence Guo-Kai Feng, Mu-Sheng Zeng, and Wei-Guang Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center/Cancer Hospital, 651 Dongfeng East Road, Guangzhou 510060, China. Email: fengguok@sysucc.org.cn (G.-K.F.); zengmsh@sysucc.org.cn (M.-S.Z.); zhangwg@sysucc.org.cn (W.G.Z.)Search for more papers by this author First published: 26 August 2020 https://doi.org/10.1002/ctm2.157Citations: 4 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Dear Editor, Recently, we successfully developed a radiolabeled probe targeting integrin α6 for the positron emission tomography (PET)/magnetic resonance (MR) imaging of pancreatic ductal adenocarcinoma (PDAC) and its precancerous lesion, pancreatic intraepithelial neoplasia (PanIN). Most pancreatic cancers are PDAC.1 Standard approaches for detecting PDAC at early stage are lacking with most diagnosed patients at advanced stage.2 Tumor-targeted molecular imaging significantly improved the tumor-detection rate,3 which may also enhance the early diagnosis of PDAC. Considering the genetic complexity of PDAC, a PDAC-specific target with highly adaptability, sensitivity, and specificity is required. We selected integrin α6 as the target of PDAC as it was overexpressed in pancreatic cancer cells4, 5 and cancerous tissue of patients with PDAC4, 6, 7 with an overexpression rate up to 92%.4 Increased integrin α6 levels were associated with stronger PDAC cell invasiveness5 and poorer prognosis for patients.6, 7 Furthermore, the integrin α6β4 dimer was overexpressed in PanIN even at a stage as early as PanIN 1A.4 Here, we confirmed that integrin α6 was overexpressed in human PDAC (Figure 1A,B) and increased integrin α6 had poorer prognosis for PDAC patients (Figure 1C). Recently, a peptide CRWYDENAC (dubbed RWY) targeting integrin α6 has been identified8 and employed for nanotherapeutics of nasopharyngeal carcinoma8 and for PET imaging of hepatocellular carcinoma by our team.9 Here, we used the Ala scanning mutagenesis to modify the RWY peptide. R, W, and Y were the three key amino acids within the RWY peptide, since their replacement by an alanine reduced the cellular binding ability of this peptide, both in vitro and in vivo. Interestingly, the alanine substitution of E resulted in the CRWYDANAC (dubbed S5) peptide with an approximately 1.5-fold enhanced tumor binding ability (Figure 1D,E). The higher binding affinity of S5 peptide to tumor cells was further confirmed in vitro by flow cytometry (Figure 1F,G) and in vivo in PDAC mouse model using optical imaging (Figure 1H,I). FIGURE 1Open in figure viewerPowerPoint Increased and poorer prognosis of integrin α6 in PDAC and the optimization of a peptide targeting integrin α6. A, According to the TCGA database, increased integrin α6 expression was observed in tumor tissues of PADC patients. B and C, Based on the GEPIA database, patients with higher integrin α6 expression in the tumor tissue showed a poorer prognosis for overall and disease-free survival. D, The binding affinities of seven Ala-mutated peptides were analyzed by ELISA. E, The in vivo blocking assays were performed via intravenous injection of 6 nmol of Cy5-RWY together with 6 μmol of the unlabeled RWY peptide, or its scrambled peptide or a set of its alanine-scanning mutant peptides into mice bearing Sw1990 tumors. The S5 peptide had the highest blocking effect on Cy5-RWY. F and G, Sw1990 cells were incubated with Cy5-RWY and Cy5-S5 at 37°C for 30 min, and the integrin α6-binding affinities of Cy5-RWY and Cy5-S5 were analyzed by flow cytometric analysis (F); the fluorescence intensity of the S5 group presented as relative (1.41 ± 0.03) fold over RWY, indicating a higher tumor cell-binding ability of S5. H and I To further investigate the in vivo tumor-binding ability of the S5 peptide, Cy5-S5, Cy5-RWY, and Cy5-CG7C (negative control) were synthesized and used in NIRF. In the in vivo NIRF imaging of mice bearing subcutaneous Sw1990-luciferase xenografts, Cy5-S5 exhibited higher fluorescence intensity in tumor location (black arrow: the xenograft) (H); the fluorescence intensity of Cy5-S5 presented as relative fold over RWY (2.64 ± 0.09) was significantly higher than that of Cy5-RWY (1.00 ± 0.10, P = .000) (mean ± SD, ANOVA in (D) and (E) and Student's t-test in (G) and (I) were used for statistical analysis. *P < .05, **P < .01, ***P < .001. NS, not significant) The recently introduced PET/MR imaging technique displays certain advantages in tumor imaging and has potential applications in the imaging of early pancreatic cancer.10 Thus, we synthesized the radiotracer 18F-NOTA-PEG4-S5 (18F-S5 for short) for the PET/MR imaging (Figure S1A). 18F-S5 was stable in serum (Figure S1B), and it showed ideal biodistribution characteristics in vivo that the uptake of 18F-S5 in tumor tissues was the highest among all collected tissues and organs except for the kidney (Figure S1C,D, Table S1). The convenience of 18F-S5-PET/MR imaging on PDAC and PanIN was proved in four mice models. Approximately 3.7 × 106 Bq (100 μCi) of 18F-S5 was intravenously injected to a mouse for PET imaging, and 2.5 mmol/kg of gadolinium-diethylenetriamine pentaacetic acid was injected for enhanced MR imaging. After 120 min postinjection of 18F-S5, PET/MR imaging was obtained by using a hybrid 3.0T PET/MR scanner (uPMR 790; UIH, Shanghai, China). The PDAC-targeting effect of 18F-S5 was preliminary examined in a subcutaneous Sw1990-luciferase tumor-bearing mouse model, where the tumor-to-muscle ratio reached 3.62 ± 0.25 in unblocked mice and significantly decreased to 1.62 ± 0.05 when the binding was blocked by nonradiolabeled S5 (Figure S2A-D). Similar results were observed in the orthotopic Sw1990-luciferase mouse model with a tumor-to-muscle ratio of 3.48 ± 0.62 (Figure S2E-G). In the genetically engineered KPC mice (LSL-KrasG12D/+; Pdx1-Cre; Trp53fl/fl) with spontaneously developed PDAC, a routine MR scan showed no abnormal signal in pancreas on T1 weighted images, and the tumor only presented as local moderate enhancement on the enhanced MR scans (Figure S3A). However, in the PET/MR imaging, 18F-S5 produced high PET signals in the possible location of the tumor (Figure 2A). The uptake of 18F-S5 in tumor was quantified as 4.34 ± 1.16 %ID/g (a percentage of the injected dose per gram) (n = 5) and the tumor-to-muscle ratio was 4.32 ± 0.65 (Figure 2B). The pancreas of the KPC mouse displayed morphological changes compared with the pancreas of a healthy mouse (Figure 2C). The overexpression of integrin α6 in the spontaneously developed PDAC tissue was confirmed using immunohistochemistry (Figure 2D). In addition, 18F-S5-PET/MR imaging could also detect metastatic tumors in KPC, where 18F-S5 produced high PET signals in both of the PDAC lesions and the metastatic tumors in the abdominal cavity (Figure S4A-D). Furthermore, 18F-S5-PET/MR imaging could detect precancerous lesions of PDAC in the KC mice (LSL-KrasG12D/+; Pdx1-Cre) with spontaneous developed PanIN (Figure 2E), which was undetectable when enhanced MR imaging was used alone (Figure S3B). 18F-S5 showed a high accumulation in the possible lesion site, as the quantified uptake was 2.99 ± 0.52 %ID/g and the PanIN-to-muscle ratio was 3.35 ± 0.43 (Figure 2F). The pancreas of the KC mouse displayed morphological changes as its outer surface was rougher (Figure 2G ) than that of the normal pancreas, as shown in Figure 2C. Immunohistochemical analysis confirmed the formation of PanIN lesions in the pancreas and increased integrin α6 expression in lesion tissues (Figure 2H). FIGURE 2Open in figure viewerPowerPoint 18F-S5 PET/MR imaging in PDAC and PanIN mouse models. A, Representative cross-sectional images of PET/MR imaging with 18F-S5 of KPC mouse (left) and the 3D image (right). B, Quantification of 18F-S5 uptake (%ID/g) by KPC mouse in tumor (4.34 ± 1.16), muscle (1.00 ± 0.17), liver (1.24 ± 0.33), and heart (2.38 ± 0.45), respectively. C, The pancreas of the KPC mouse showed an abnormal appearance compare to the pancreas of a healthy mouse. D, The development of PDAC in KPC mouse was confirmed by HE staining (left), and increased integrin α6 expression was confirmed by immunohistochemistry (right). E, Representative cross-sectional images of PET/MR imaging of KC mouse (left) and the MIP reconstructed image (right). F, Quantification of 18F-S5 uptake (%ID/g) by KC mouse in PanIN tissue (2.99 ± 0.52), muscle (0.89 ± 0.13), liver (1.31 ± 0.22), and heart (2.43 ± 0.35), respectively. G, The pancreas of the KPC mouse showed an abnormal appearance compare to the pancreas of a healthy mouse. H, The development of PanIN in mice was confirmed by HE staining (left), and the overexpression of integrin α6 in the lesion was analyzed using immunohistochemistry (right) (red arrow: PanIN; black arrow: relatively normal pancreatic tissue) (mean ± SD, the difference was evaluated by Student's t-test, *P < .05, **P < .01, ***P < .001) In summary, we developed an optimized integrin α6-targeted radiolabeled probe, 18F-S5, for PET/MR imaging of PDAC and PanIN in mice models. 18F-S5 displayed ideal stability and biodistribution characteristics, and it enabled the detection of PDAC at an early stage with high sensitivity, a favorable tumor-to-muscle ratio, and low liver uptake in mice, which suggests its potential clinical translation. ACKNOWLEDGMENTS This work was supported by grants from the National Key R&D Program of China (2017YFA0505600 and 2016YFA0502100), the National Natural Science Foundation of China (NSFC) (projects 81972531, 81602364, 81621004, 81520108022, and 81572403), the National Science & Technology Major Project (2017ZX09304021), and the Science & Technology Project of Guangdong Province (2017A020211010). The approval Research Data Deposit number was RDDB2020000944. CONFLICT OF INTEREST The authors have declared that no competing interest exists. ETHICS APPROVAL The animal experiments were approved by the animal welfare and ethics committees of Sun Yat-sen University Cancer Center. Open Research DATA AVAILABILITY STATEMENT The raw data used in this article have been uploaded onto the Research Data Deposit public platform (www.researchdata.org.cn). Supporting Information Filename Description ctm2157-sup-0001-SuppMat.docx245.1 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019; 69(1): 7- 34. 2Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016; 388(10039): 73- 85. 3Yao VJ, D'Angelo S, Bulter KS, et al. Ligand-targeted theranostic nanomedicines against cancer. J Control Release. 2016; 240: 267- 286. 4Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL. Upregulation and redistribution of integrin α6β4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol. 2007; 20(6): 656- 667. 5Wu Y, Tan X, Liu P, et al. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Exp Cell Res. 2019; 379(1): 30- 47. 6Sawai H, Funahashi H, Matsuo Y, et al. Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci. 2003; 48(7): 1241- 1250. 7Zhu G, Huang C, Qiu Z, et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011; 56(4): 1090- 1098. 8Feng G, Zhang M, Wang H, et al. Identification of an integrin α6-targeted peptide for nasopharyngeal carcinoma-specific nanotherapeutics. Adv Therap. 2019; 2:1900018. 9Feng G, Ye J, Zhang W, et al. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. J Control Release. 2019; 310: 11- 21. 10Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdom Radiol. 2018; 43(2): 415- 434. Citing Literature Volume10, Issue4August 2020e157 FiguresReferencesRelatedInformation

Abstract:Future OncologyVol. 17, No. 4 EditorialClinical application of multigene expression assays in the era of sentinel lymph node biopsyXue-Er Wang‡, Zhao Bi‡, Ying Liang, Peng-Peng Zhou, Peng Chen, Peng-Fei Qiu, Bin-Bin Cong, Xian-Rang Song & Yong-Sheng WangXue-Er Wang‡Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR China‡These authors contributed equally to this work and should be considered co-first authorsSearch for more papers by this author, Zhao Bi‡ https://orcid.org/0000-0001-9546-1704Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR China‡These authors contributed equally to this work and should be considered co-first authorsSearch for more papers by this author, Ying LiangShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaCheeloo college of Medicine, Shandong university, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author, Peng-Peng ZhouShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author, Peng ChenShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaCheeloo college of Medicine, Shandong university, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author, Peng-Fei QiuShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author, Bin-Bin CongShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author, Xian-Rang SongShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this author & Yong-Sheng Wang*Author for correspondence: Tel.: +86 0531 6762 6211; E-mail Address: wangysh2008@aliyun.comShandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, Shandong, PR ChinaSearch for more papers by this authorPublished Online:11 Dec 2020https://doi.org/10.2217/fon-2020-0932AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: axillary lymph node dissectionde-escalation managementmulti-gene expression assayssentinel lymph node biopsyReferences1. Lerna CO, Armando EG, Frcsedis I. Axillary lymph node dissection necessary after a positive sentinel lymph node biopsy? Adv. Surg. 51(1), 165–178 (2017).Crossref, Medline, Google Scholar2. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized Phase 3 trial. Lancet Oncol. 11(10), 927–933 (2010).Crossref, Medline, Google Scholar3. Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann. Surg. 252(3), 426–432 (2010).Crossref, Medline, Google Scholar4. Donker M, van Tienhoven G, Straver ME et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomized, multicenter, open-label, Phase 3 non-inferiority trial. Lancet Oncol. 15(12), 1303–1310 (2014).Crossref, Medline, Google Scholar5. Savolt A, Peley G, Polgar C et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, Phase III, non-inferiority trial. Eur. J. Surg. Oncol. 43(4), 672–679 (2017).Crossref, Medline, CAS, Google Scholar6. Armando EG, Kelly KH, Karla VB et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6), 569–575 (2011).Crossref, Medline, Google Scholar7. Cardoso F, vantVeer LJ, Bogaerts J et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375(8), 717–729 (2016).Crossref, Medline, CAS, Google Scholar8. Burstein HJ, Curigliano G, Loibl S et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 30(10), 1541–1557 (2019).Crossref, Medline, CAS, Google Scholar9. Stella M, Marjanka KS, Giuseppe V et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 116(3), 295–302 (2009).Medline, Google Scholar10. Kuru B, Yuruker S, Sullu Y et al. Management of the axilla in T1–2 breast cancer patients with macro-metastatic sentinel node involvement who underwent breast-conserving therapy. J. Invest. Surg. 32(1), 48–54 (2019).Crossref, Medline, Google Scholar11. Shahab FA, Emmanuel EZ, Manju P et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am. J. Surg. 182(4), 316–320 (2001).Crossref, Medline, Google Scholar12. Sandra LW, Michael JE, Celia C et al. Predicting the status of the non-sentinel axillary nodes: a multicenter study. Arch. Surg. 136(5), 563–568 (2001).Crossref, Medline, Google Scholar13. Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer – a multicenter validation study. N. Engl. J. Med. 339(14), 941–946 (1998).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByCandidates of Genomic Tests in HR+/HER2- Breast Cancer Patients With 1-2 Positive Sentinel Lymph Node Without Axillary Lymph Node Dissection: Analysis From Multicentric Cohorts5 August 2021 | Frontiers in Oncology, Vol. 11 Vol. 17, No. 4 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 31 times History Received 10 September 2020 Accepted 25 September 2020 Published online 11 December 2020 Published in print February 2021 Information© 2020 Future Medicine LtdKeywordsaxillary lymph node dissectionde-escalation managementmulti-gene expression assayssentinel lymph node biopsyFinancial & competing interests disclosureThis work was funded by National Natural Science Foundation of China (no. 81672638 and 81672104) and Shandong Provincial Key Research and Development Program (no. 2017CXGC1207, 2019GSF108179 and 2019GSF108104). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download

Myoepithelial Hyperplasia: A Rare Mimic of Breast Cancer on 18 F‐FDG PET/CT

Abstract 5622: Integrative cross-platform characterisation of mammographic screen-detected breast cancer

The Application of Intraoperative Specimen Mammography for Margin Status Assessment in Breast‐conserving Surgery: A Single‐center Retrospective Study

Myoid Harmatoma of the Breast: Clinicopathologic Analysis of a Rare Tumor Indicating Occasional Recurrence Potential

Hepatoma-derived Growth Factor is a Novel Prognostic Factor for Cervical Squamous Cell Carcinoma

P1119 Comparative Study of Neoadjuvant Intravenous Versus Intraarterial Chemotherapy Versus Brachytherapy Followed by Radical Surgery Versus Radical Surgery Alone in Stage IB2–IIA Bulky Cervical Cancers: a Phase III Randomized Clinical Trial in Shanghai

A Novel Technique for Localization of Sentinel Lymph Node in Breast Cancer Patients Based on Computed Tomographic Lymphography

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

A Huge Borderline Phyllodes Breast Tumors

An Unusual Magnetic Resonance Imaging of a Giant Cystic Volume of Tubular Adenoma of the Breast

A Reflection on Noninvasive Molecular Imaging of Cancer Spread to Lymph Nodes

Kutane Metastasen Eines Dreifachen Primären Extramammären Morbus Paget

Palmoplantar Keratoderma: a New Phenotype in Patients with Hypotrichosis Resulted from Lanosterol Synthase Gene Mutations

Comment on Stereotactic Body Radiation Therapy for Small Primary or Recurrent Hepatocellular Carcinoma—authors’ Reply

Visualizing Transgenic Murine Papillary Thyroid Cancer with Novel Nerve Peptide and Protease‐dependent Tumor‐targeting Peptides

Operating Microscope with Near Infrared Imaging Function for Indocyanine Green Lymphography in Prevention of Lymphedema with Lymphaticovenous Anastomosis Immediately after Mastectomy and Axillary Dissection

Surgical Resection of Lung Adenocarcinoma Without EGFR Mutation after Neoadjuvant Gefitinib Treatment

Clinical Application of Multigene Expression Assays in the Era of Sentinel Lymph Node Biopsy.

Cutaneous Metastases from Triple Primary Extramammary Paget's Disease

Bone Marrow Involvement by Breast Implant‐associated Anaplastic Large Cell Lymphoma

Overexpression of Trefoil Factor 1 and Trefoil Factor 3 in Primary Extramammary Paget's Disease and Implication of a Novel Therapeutic Target